Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VOR
- Price
- 0.70
- Stock movement up
- +0.08 (12.27%)
- Company name
- Vor Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 48.07M
- Ent value
- 38.31M
- Price/Sales
- 3.93
- Price/Book
- 0.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -64.47%
- 3 year return
- -50.61%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VOR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.93 |
| Price to Book | 0.66 |
| EV to Sales | 3.13 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.67M |
| EPS (TTM) | -1.64 |
| FCF per share (TTM) | -1.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.23M |
| Gross profit (TTM) | 9.49M |
| Operating income (TTM) | -118.00M |
| Net income (TTM) | -112.46M |
| EPS (TTM) | -1.64 |
| EPS (1y forward) | -1.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 77.63% |
| Operating margin (TTM) | -965.14% |
| Profit margin (TTM) | -919.87% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 52.80M |
| Net receivables | 0.00 |
| Total current assets | 67.30M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 115.99M |
| Accounts payable | 1.32M |
| Short/Current long term debt | 32.85M |
| Total current liabilities | 14.35M |
| Total liabilities | 43.04M |
| Shareholder's equity | 72.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -99.62M |
| Capital expenditures (TTM) | 268.00K |
| Free cash flow (TTM) | -99.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -154.15% |
| Return on Assets | -96.96% |
| Return on Invested Capital | -145.83% |
| Cash Return on Invested Capital | -129.53% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.63 |
| Daily high | 0.70 |
| Daily low | 0.62 |
| Daily Volume | 179K |
| All-time high | 54.08 |
| 1y analyst estimate | 13.21 |
| Beta | -0.41 |
| EPS (TTM) | -1.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| VOR | S&P500 | |
| Current price drop from All-time high | -98.71% | -12.89% |
| Highest price drop | -98.99% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -86.04% | -11.07% |
| Avg time to new high | 132 days | 12 days |
| Max time to new high | 1038 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
48.07M
Marketcap category
Small-cap
Description
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees
168
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page